These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 25208882

  • 21. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC.
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [Abstract] [Full Text] [Related]

  • 22. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 23. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA, Kim LH, Lee SJ, Jeong JH, Jung JY, Lee HN, Hong IS, Cho SD.
    Oncotarget; 2015 Nov 03; 6(34):35667-83. PubMed ID: 26447615
    [Abstract] [Full Text] [Related]

  • 24. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.
    Breast Cancer Res; 2012 Jun 15; 14(3):R96. PubMed ID: 22703841
    [Abstract] [Full Text] [Related]

  • 25. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT, Elkholi R, Bharti A, Chipuk JE.
    J Biol Chem; 2014 Sep 19; 289(38):26481-26491. PubMed ID: 25096574
    [Abstract] [Full Text] [Related]

  • 26. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.
    Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ.
    Cancer Cell; 2013 Jul 08; 24(1):120-9. PubMed ID: 23845444
    [Abstract] [Full Text] [Related]

  • 27. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
    Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis RE, Andreeff M.
    Biochim Biophys Acta; 2016 Apr 08; 1863(4):562-71. PubMed ID: 26704388
    [Abstract] [Full Text] [Related]

  • 28. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH.
    Blood; 2021 May 20; 137(20):2721-2735. PubMed ID: 33824975
    [Abstract] [Full Text] [Related]

  • 29. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM, Min KJ, Seo BR, Nam JO, Choi KS, Yoo YH, Kwon TK.
    Cell Death Dis; 2014 Nov 06; 5(11):e1514. PubMed ID: 25375379
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.
    Blood; 2015 Jul 16; 126(3):363-72. PubMed ID: 26045609
    [Abstract] [Full Text] [Related]

  • 31. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
    Stauffer SR.
    Curr Top Med Chem; 2007 Jul 16; 7(10):961-5. PubMed ID: 17508927
    [Abstract] [Full Text] [Related]

  • 32. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S.
    PLoS One; 2013 Jul 16; 8(11):e78570. PubMed ID: 24223823
    [Abstract] [Full Text] [Related]

  • 33. YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.
    Woo SM, Min KJ, Seo BR, Seo YH, Jeong YJ, Kwon TK.
    Mol Cell Biochem; 2017 May 16; 429(1-2):91-102. PubMed ID: 28120212
    [Abstract] [Full Text] [Related]

  • 34. Dihydroartemisinin Enhances the Therapeutic Efficacy of BH3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells via Inhibition of Mcl-1.
    Nazmabadi R, Pooladi M, Amri J, Abbasi Y, Karami H, Darvish M.
    Asian Pac J Cancer Prev; 2024 Jan 01; 25(1):325-332. PubMed ID: 38285800
    [Abstract] [Full Text] [Related]

  • 35. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L, Dittmann J, Vogler M, Fulda S.
    Cell Death Dis; 2019 Dec 04; 10(12):917. PubMed ID: 31801941
    [Abstract] [Full Text] [Related]

  • 36. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.
    Cancer Res; 2007 Feb 01; 67(3):1176-83. PubMed ID: 17283153
    [Abstract] [Full Text] [Related]

  • 37. Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.
    Harrison LR, Micha D, Brandenburg M, Simpson KL, Morrow CJ, Denneny O, Hodgkinson C, Yunus Z, Dempsey C, Roberts D, Blackhall F, Makin G, Dive C.
    J Clin Invest; 2011 Mar 01; 121(3):1075-87. PubMed ID: 21393866
    [Abstract] [Full Text] [Related]

  • 38. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.
    Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, Morrow CJ.
    Neoplasia; 2014 Feb 01; 16(2):147-57. PubMed ID: 24709422
    [Abstract] [Full Text] [Related]

  • 39. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
    Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M.
    J Mol Med (Berl); 2013 Dec 01; 91(12):1383-97. PubMed ID: 23955073
    [Abstract] [Full Text] [Related]

  • 40. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.
    Clin Cancer Res; 2011 Sep 15; 17(18):5973-81. PubMed ID: 21821698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.